EndoPAT Device for Endothelial Dysfunction in ED
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18+
SponsorUniversity of California, Irvine
About this trial
To assess endothelial dysfunction in young men (aged 30-50) with vasculogenic ED identified through penile Doppler ultrasound.
To evaluate changes in endothelial function using EndoPAT before and 3-6 months after daily low-dose phosphodiesterase type 5 (PDE5) inhibitor therapy.
To investigate endothelial function alterations in hypogonadal patients before and 3-6 months after initiating testosterone (T) therapy
Eligibility criteria
Qualifiers
Males 18 years old and above
Diagnosed with erectile dysfunction or hypogonadism
Disqualifiers
Patients without the above criteria
Trial design
Treatments tested in this trial
- Daily low-dose PDE5 inhibitor therapy
- Testosterone therapy as per clinical guidelines.
Treatment groups
120 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov